Biomedical Center in Moscow has developed a peptide formulation that induces activation and proliferation of the cytotoxic lymphocyte’s (CTL) clones and enables them to recognize and selectively kill Listeria infected cells. As the lifetime of CTL clones is 3 to 7 years or more the formulation could be used for both prophylaxis and treatment. The developer is looking for support/collaboration to implement the following three stages: promoting the peptide preparation as a veterinarian vaccine; promoting the peptide preparation as human vaccine; and promoting the peptide preparation in Europe and other markets.
The developed peptide preparation may be administered intranasal (for humans), subcutaneusly (for humans and animals), transcutaneusly (humans), and gastroenternally (humans and animals).
Get the complete report on this technology at: